Based on data from multiple clinical trials, the FDA has approved obinutuzumab for the treatment of adults with lupus nephritis in combination with standard therapy.
Latest News
Hip Replacements at 14,000 Feet: A Joint Doctor with Joint Disease, Part 2
Dr. Sam Shapiro writes about her recovery from total hip arthroplasty, detailing what “recovering well with no post-operative complications” really meant and her experience hiking in the Himalayas with a new hip.
Clinical Manifestations of VEXAS
Anderson et al. studied genetic data on more than 190,000 participants and found 23 who had genetic variants in the UBA1 gene, which is associated with VEXAS.
RA Research Presented at ACR Convergence 2025 in Focus
This synopsis of research into rheumatoid arthritis highlights key areas presented at ACR Convergence 2025, including strategies to delay or prevent RA, emerging mechanisms of action in RA treatment, and the growing role of AI in advancing RA research and clinical care.
The Promise of Hope in Lupus Nephritis
Explore the latest lupus nephritis advances in this supplement, covering CAR-T therapy, obinutuzumab data & new diagnostic tools.
Insights into SLE & Lupus Nephritis From the 2025 Review Course
Review expert strategies & clinical pearls for managing SLE & lupus nephritis. Get therapeutic updates from the ACR’s 2025 Review Course.
